Cabazitaxel
In the US, Cabazitaxel (cabazitaxel systemic) is a member of the drug class mitotic inhibitors and is used to treat Prostate Cancer.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L01CD04
CAS registry number (Chemical Abstracts Service)
0183133-96-2
Chemical Formula
C45-H57-N-O14
Molecular Weight
836
Therapeutic Categories
Cytostatic agent
Microtubule inhibitor
Taxane
Chemical Names
(2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimetoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate-propan-2-one (1:1)
1-hydroxy-7β,10β-dimetyoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate] (WHO)
Foreign Names
- Cabazitaxelum (Latin)
- Cabazitaxel (German)
- Cabazitaxel (French)
- Cabazitaxel (Spanish)
Generic Names
- Cabazitaxel (OS: USAN, BAN)
- RPR 116258A (IS)
- Taxoid XRP6258 (IS)
- TXD 258 (IS)
- XRP 6258 (IS)
Brand Names
- Cabazil
Varifarma, Argentina - Cecalter
Tuteur, Argentina - Jevtana
Aventis, Serbia; Orifarm, Norway; Sanofi, Denmark; Sanofi, Dominican Republic; Sanofi, United Kingdom; Sanofi, Guatemala; Sanofi, Ireland; Sanofi, Japan; Sanofi, Panama; Sanofi, Sweden; Sanofi Aventis, Chile; Sanofi Belgium, Belgium; Sanofi Clir SNC, Greece; Sanofi Franta, Romania; Sanofi Israel, Israel; Sanofi Oy, Finland; Sanofi Sağlik, Turkey; Sanofi-Aventis, Argentina; Sanofi-Aventis, Australia; Sanofi-Aventis, Bosnia & Herzegowina; Sanofi-Aventis, Canada; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Cyprus; Sanofi-Aventis, Czech Republic; Sanofi-Aventis, Estonia; Sanofi-Aventis, Spain; Sanofi-Aventis, France; Sanofi-Aventis, Hong Kong; Sanofi-Aventis, Honduras; Sanofi-Aventis, Croatia (Hrvatska); Sanofi-Aventis, Indonesia; Sanofi-Aventis, Iceland; Sanofi-Aventis, Lithuania; Sanofi-Aventis, Malaysia; Sanofi-Aventis, Nicaragua; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Norway; Sanofi-Aventis, Philippines; Sanofi-Aventis, Poland; Sanofi-Aventis, Singapore; Sanofi-Aventis, Slovakia; Sanofi-Aventis, El Salvador; Sanofi-Aventis, Thailand; Sanofi-Aventis, United States; Sanofi-Aventis Deutschland, Germany; Sanofi-Aventis Farmaceutica, Brazil; Sanofi-Aventis Groupe, Slovenia - Jevtana 60mg
Haemato Pharm, Austria; Orifarm, Austria; Sanofi Belgium, Luxembourg; Sanofi-Aventis, Austria; Sanofi-Aventis, Switzerland; Sanofi-Aventis, Hungary; Sanofi-Aventis, Oman - Proazitax
Eurofarma, Brazil - Zitat
LKM, Argentina
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
